Diabetes Drugs Linked to Lower Risk of Dementia and Parkinson's

A South Korean study finds that SGLT2 inhibitors can significantly reduce the risk of neurodegenerative diseases in type 2 diabetes patients.

The study followed 358,862 participants with type 2 diabetes over an average of 9.6 years.
Patients taking SGLT2 inhibitors had a 22% lower risk of developing dementia or Parkinson's compared to those on other diabetes medications.
Specifically, the risk was reduced by 19% for Alzheimer's, 20% for Parkinson's, and 31% for vascular dementia.
Researchers believe the drugs' impact on glucose metabolism and ketone production may contribute to these protective effects.
Further research is needed to confirm these findings and explore potential benefits for non-diabetic individuals.